{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:52:46Z","timestamp":1794513166464,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Evaluate the safety and efficacy of the Janus kinase (JAK)1\/JAK2 inhibitor ruxolitinib in COVID-19\u2013associated acute respiratory distress syndrome requiring mechanical ventilation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Phase 3 randomized, double-blind, placebo-controlled trial Ruxolitinib in Participants With COVID-19\u2013Associated Acute Respiratory Distress Syndrome Who Require Mechanical Ventilation (RUXCOVID-DEVENT; NCT04377620).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Hospitals and community-based private or group practices in the United States (29 sites) and Russia (4 sites).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Eligible patients were greater than or equal to 12 years old, hospitalized with severe acute respiratory syndrome coronavirus 2 infection, and mechanically ventilated with a Pa<jats:sc>o<\/jats:sc>\n                                 <jats:sub>2<\/jats:sub>\/F<jats:sc>io<\/jats:sc>\n                                 <jats:sub>2<\/jats:sub> of less than or equal to 300\u2009mm Hg within 6 hours of randomization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>Patients were randomized 2:2:1 to receive twice-daily ruxolitinib 15\u2009mg, ruxolitinib 5\u2009mg, or placebo, each plus standard therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>The primary endpoint, 28-day mortality, was tested for each ruxolitinib group versus placebo using a mixed-effects logistic regression model and one-tailed significance test (significance threshold: <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.025); no type 1 error was allocated to secondary endpoints. Between May 24, 2020 and December 15, 2020, 211 patients (age range, 24\u201387 yr) were randomized (ruxolitinib 15\/5\u2009mg, <jats:italic toggle=\"yes\">n<\/jats:italic> = 77\/87; placebo, <jats:italic toggle=\"yes\">n<\/jats:italic> = 47). Acute respiratory distress syndrome was categorized as severe in 27% of patients (58\/211) at randomization; 90% (190\/211) received concomitant steroids. Day-28 mortality was 51% (39\/77; 95% CI, 39\u201362%) for ruxolitinib 15\u2009mg, 53% (45\/85; 95% CI, 42\u201364%) for ruxolitinib 5\u2009mg, and 70% (33\/47; 95% CI, 55\u201383%) for placebo. Neither ruxolitinib 15\u2009mg (odds ratio, 0.46 [95% CI, 0.201\u20131.028]; one-sided <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.029) nor 5\u2009mg (odds ratio, 0.42 [95% CI, 0.171\u20131.023]; one-sided <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.028) significantly reduced 28-day mortality versus placebo. Numerical improvements with ruxolitinib 15\u2009mg versus placebo were observed in secondary outcomes including ventilator-, ICU-, and vasopressor-free days. Rates of overall and serious treatment-emergent adverse events were similar across treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>The observed reduction in 28-day mortality rate between ruxolitinib and placebo in mechanically ventilated patients with COVID-19\u2013associated acute respiratory distress syndrome was not statistically significant; however, the trial was underpowered owing to early termination.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000005682","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T13:00:45Z","timestamp":1665666045000},"page":"1701-1713","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":39,"title":["Randomized Phase 3 Trial of Ruxolitinib for COVID-19\u2013Associated Acute Respiratory Distress Syndrome*"],"prefix":"10.1097","volume":"50","author":[{"given":"Lindsay","family":"Rein","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Calero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pulmonary Critical Care and Sleep Medicine, University of South Florida, Tampa, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Hackensack Meridian School of Medicine, Hackensack, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ojielo","sequence":"additional","affiliation":[{"name":"Section of Critical Care Medicine, Aurora St. Luke\u2019s Medical Center, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Hudock","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care & Sleep Medicine, University of Cincinnati School of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Lodhi","sequence":"additional","affiliation":[{"name":"Pulmonology, Confluence Health, Wenatchee, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Sadaka","sequence":"additional","affiliation":[{"name":"Trauma and Neurologic Intensive Care Unit, Mercy Hospital, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Bellam","sequence":"additional","affiliation":[{"name":"Department of Medicine, NorthShore University HealthSystem, Evanston, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Palma","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Hager","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Daniel","sequence":"additional","affiliation":[{"name":"Clinical Development, Incyte Corporation, Wilmington, DE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schaub","sequence":"additional","affiliation":[{"name":"Clinical Development, Incyte Corporation, Wilmington, DE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"O\u2019Hayer","sequence":"additional","affiliation":[{"name":"Clinical Development, Incyte Corporation, Wilmington, DE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Theodoropoulos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases & Immunology, UMass Memorial Medical Center, Worcester, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"382","DOI":"10.15585\/mmwr.mm6913e2","article-title":"Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020.","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s13054-020-03240-7","article-title":"Incidence of ARDS and outcomes in hospitalized patients with COVID-19: A global literature survey.","volume":"24","author":"Tzotzos","year":"2020","journal-title":"Crit Care"},{"key":"R5-20250502","first-page":"2526","article-title":"Acute respiratory distress syndrome: The Berlin definition.","volume":"307","year":"2012","journal-title":"JAMA"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20\u2009133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study.","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19.","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial.","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19.","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"eabg9873","DOI":"10.1126\/sciimmunol.abg9873","article-title":"Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19.","volume":"6","author":"Thwaites","year":"2021","journal-title":"Sci Immunol"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia.","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20250502","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial.","author":"Horby","year":"2021","journal-title":"Lancet"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia.","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression.","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis.","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: An open-label, single-centre, pilot trial.","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/s41375-021-01412-0","article-title":"Publisher Correction: The Janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).","volume":"35","author":"Neubauer","year":"2021","journal-title":"Leukemia"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19.","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with COVID-19 pneumonia.","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUS of the Lombardy region, Italy.","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40121-020-00326-1","article-title":"Interleukin-6 blocking vs. JAK-STAT inhibition for prevention of lung injury in patients with COVID-19.","volume":"9","author":"Meletiadis","year":"2020","journal-title":"Infect Dis Ther"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19.","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial.","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/d41573-021-00037-3","article-title":"Trends in COVID-19 therapeutic clinical trials.","volume":"20","author":"Bugin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3904\/kjim.2020.619","article-title":"Corticosteroids in acute respiratory distress syndrome: Outcomes obscured by mortality.","volume":"36","author":"Oh","year":"2021","journal-title":"Korean J Intern Med"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"211","DOI":"10.12788\/jhm.3539","article-title":"Analysis of hospital resource availability and COVID-19 mortality across the United States.","volume":"16","author":"Janke","year":"2021","journal-title":"J Hosp Med"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000005682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:03:27Z","timestamp":1746205407000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000005682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000005682","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,13]]}}}